Mason Carrico's questions to Neogenomics Inc (NEO) leadership • Q1 2025
Question
Mason Carrico of Stephens Inc. asked if expectations for the core NeoGenomics ASP runway have changed and about the mix of volume versus ASP growth for the year. He also inquired about the timeline for driving adoption of the broader NeoGenomics portfolio within the newly acquired Pathline customer base.
Answer
CFO Jeff Sherman stated that revenue growth in 2025 will likely be more heavily weighted to volume than AUP, partly due to business mix, though progress on AUP continues at the modality level. Head of Strategy Kareem Saad explained that cross-selling into the Pathline customer base will see minimal benefit this year, as it will take a couple of quarters to complete test validations in the Pathline lab. He expects a more significant benefit starting in Q4 and more fully in Q1 of the next year.